Positron emission tomography (PET) using a variety of tracers can reliably detect sites of prostate cancer before abnormalities can be appreciated using conventional imaging, particularly with respect to local recurrence and metastatic disease and 68Ga labelled PSMA ([68Ga]Ga-PSMA-11) tracer is the most widely reported.1 Our prospective study adds to the existing literature assessing the role of PSMA PET/CT in patients with detectable PSA post-prostatectomy, specifically with the [18F]DCFPyL tracer. This study recruited just under 100 men with a PSA between 0.2-2.0ng/mL being considered for salvage radiotherapy, and the majority of men had a PSA <0.5 ng/mL (median PSA of 0.32ng/mL). Local recurrences at the anastomosis or seminal vesicle bed was 28.5%, nodal disease detected in 27.5%, and bone metastases in 6.1% of patients. Our study also reported the positive detection rate with diagnostic CT chest abdomen and pelvis, which lacks a functional imaging component, reporting a 15.5% detection rate.